Search
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]
Pepsin
go.drugbank.com/drugs/DB13198ApprovedWithdrawnSoon afterward, it was shown that these protein nutrients were cleaved by pepsin to products called _peptones_ [A32603]. … Pepsin is approved by the FDA and is used in food at levels not to exceed current good manufacturing practice [L2363].
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalIntravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants. … Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac]
Products: Nu-indo Cap 50mg, Indocid Sup 50mgPentaerythritol tetranitrate
go.drugbank.com/drugs/DB06154ApprovedWithdrawnIt is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is formed by reacting pentaerythritol (C5H12O4), an alcohol commonly used in paints and varnishes, with nitric acid (HNO2). The reacting solution is chilled to precipitate the PETN.
Products: Peritrate Tab 10mg, Peritrate Tab 20mgEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalMyasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalIt is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458
Dimercaprol
go.drugbank.com/drugs/DB06782ApprovedDimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigational[A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
Phenoxyethanol
go.drugbank.com/drugs/DB11304ApprovedInvestigationalPhenoxyethanol has been classified as an antimicrobial and preservative by Health Canada [L2623]. … It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621].